Compare NGEN & PPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NGEN | PPHC |
|---|---|---|
| Founded | 2017 | N/A |
| Country | Canada | United States |
| Employees | 14 | 447 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 396.4M |
| IPO Year | N/A | 2026 |
| Metric | NGEN | PPHC |
|---|---|---|
| Price | $3.73 | $13.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 208.7K | 50.0K |
| Earning Date | 04-02-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.51 | $11.25 |
| 52 Week High | $5.93 | $15.15 |
| Indicator | NGEN | PPHC |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 47.96 |
| Support Level | $3.65 | $12.94 |
| Resistance Level | $4.44 | $14.48 |
| Average True Range (ATR) | 0.21 | 0.74 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 20.36 | 21.72 |
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations.